AOD-9604 tracker
Educational reference for AOD-9604. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
2 h
Tmax
0.5 h
Category
peptide
> PLACEHOLDER — pending clinical review by licensed pharmacist. AOD-9604 is a synthetic C-terminal fragment of human growth hormone (amino acids 177-191) that has been investigated for its purported lipolytic activity. The proposed mechanism is independent of the GH receptor, instead acting through direct stimulation of adipocyte lipolysis via the beta-adrenergic pathway. Its half-life is approximately 2 hours. AOD-9604 has been studied in clinical trials for obesity but has not received FDA approval. Users tracking AOD-9604 should document dosing, injection sites, and weight or body-composition changes over time.
Mechanism
A synthetic peptide fragment derived from the C-terminal region of human growth hormone. In preclinical work it has been studied for possible effects on fat metabolism without the full growth-promoting activity of intact growth hormone. Human mechanistic data are limited.
Research summary
Early human trials evaluated it for obesity but did not establish clear efficacy, and it is not FDA-approved for weight management. Most supportive evidence is preclinical. Claims should be read against that evidence gap.
Dosing in the literature
Some early trials used oral or subcutaneous administration under study protocols. There is no approved clinical regimen; this summary does not provide dosing.
Reported side effects
Early trials reported general tolerability, but controlled long-term human safety data are limited. Sourcing and purity are recurring quality concerns.
Stacking notes
Discussed anecdotally in body-composition contexts; there is no controlled human evidence supporting specific combinations.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- AOD-9604 obesity clinical study · peer-reviewed clinical trial (2011)search PubMed for AOD9604 obesity
- Regulatory status note · FDA / regulatory guidance (2024)not FDA-approved for weight management; verify current status
References
- AOD-9604 clinical trialDOI: 10.1530/eje.0.1480101
Track AOD-9604 in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.